Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Highly Accessed Case report

Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease

Katja Thomas1, Hagen Schrötter2, Michael Halank3 and Tjalf Ziemssen1*

Author Affiliations

1 Center of Clinical Neuroscience, Department of Neurology, Neurological University Clinic Dresden, University Clinic Carl Gustav Carus Dresden, University of Technology Dresden, Fetscherstr, 74, 01307 Dresden, Germany

2 Dresden Heart Center, University Clinic Carl Gustav Carus Dresden, University of Technology Dresden, Fetscherstr, 76, 01307 Dresden, Germany

3 Department of Internal Medicine I, University Clinic Carl Gustav Carus Dresden, University of Technology Dresden, Fetscherstr, 74, 01307 Dresden, Germany

For all author emails, please log on.

BMC Neurology 2014, 14:126  doi:10.1186/1471-2377-14-126

Published: 7 June 2014

Abstract

Background

Fingolimod is the first oral immunomodulatory therapy approved for highly active relapsing remitting multiple sclerosis. Based on the distribution pattern of fingolimod interacting sphingosine-1-phosphat receptors in organism including immune system and cardiovascular system clinical monitoring of patients and evaluation of adverse events are recommended. Despite extensive data on cardiovascular safety, experience with fingolimod in patients with concomitant cardiological disease, especially within the pulmonary circulation, is rare.

Case presentation

We report the case of a 46-year-old woman presented with relapsing remitting multiple sclerosis and severe idiopathic pulmonary arterial hypertension. Fingolimod was initiated because of disease activity of multiple sclerosis with two relapses and gadolinium-enhancing lesions in MRI. The patient demonstrated stable disease course of idiopathic pulmonary arterial hypertension when fingolimod was started. Fingolimod therapy did not alter or even worsen the pulmonary or cardiovascular conditions during first dose application as well as follow up of nine months.

Conclusion

In this report, we present the first case of fingolimod treatment in a patient with highly active multiple sclerosis and severe idiopathic pulmonary arterial hypertension. We suggest an interdisciplinary approach with detailed cardiopulmonary monitoring for safety in such patients.

Keywords:
Multiple sclerosis; Fingolimod; Pulmonary arterial hypertension